Yi Larson

2021 - Turning Point Therapeutics

In 2021, Yi Larson earned a total compensation of $3.9M as Former Executive Vice President and Chief Financial Officer at Turning Point Therapeutics, a 72% increase compared to previous year.

Compensation breakdown

Option Awards$1,996,207
Salary$109,789
Stock Awards$1,766,506
Total$3,872,502

Larson received $2M in option awards, accounting for 52% of the total pay in 2021.

Larson also received $109.8K in salary and $1.8M in stock awards.

Rankings

In 2021, Yi Larson's compensation ranked 3,454th out of 12,415 executives tracked by ExecPay. In other words, Larson earned more than 72.2% of executives.

ClassificationRankingPercentile
All
3,454
out of 12,415
72nd
Division
Manufacturing
1,410
out of 5,505
74th
Major group
Chemicals And Allied Products
569
out of 2,375
76th
Industry group
Drugs
507
out of 2,096
76th
Industry
Pharmaceutical Preparations
353
out of 1,546
77th
Source: SEC filing on April 29, 2022.

Larson's colleagues

We found six more compensation records of executives who worked with Yi Larson at Turning Point Therapeutics in 2021.

2021

Athena Countouriotis

Turning Point Therapeutics

Chief Executive Officer

2021

Mohammad Hirmand

Turning Point Therapeutics

Chief Medical Officer

2021

Annette North

Turning Point Therapeutics

General Counsel

2021

Paolo Tombesi

Turning Point Therapeutics

Chief Financial Officer

2021

Siegfried PHD

Turning Point Therapeutics

Chief Scientific Officer

2021

Brian Baker

Turning Point Therapeutics

Former Senior Vice President, Finance and Administration

News

In-depth

You may also like